Pomalidomide

Pomalidomide, the third-generation immunomodulatory agent, acts as molecular glue. Pomalidomide interacts with the E3 ligase cereblon and induces degradation of essential Ikaros transcription factors.

Product Specifications

CAS Number

[19171-19-8]

Product Name Alternative

CC-4047

UNSPSC

12352005

Hazard Statement

H360

Target

Apoptosis; Ligands for E3 Ligase; Molecular Glues

Type

Reference compound

Related Pathways

Apoptosis; PROTAC

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/Pomalidomide.html

Purity

99.96

Solubility

DMSO : 50 mg/mL (ultrasonic)

Smiles

O=C1N(C(C2=C1C=CC=C2N)=O)C(C(N3)=O)CCC3=O

Molecular Formula

C13H11N3O4

Molecular Weight

273.24

Precautions

H360

References & Citations

[1]Zhu YX, et al. Molecular mechanism of action of the immune-modulatory drugs, thalidomide, lenalidomide and pomalidomide in multiple myeloma. Leuk Lymphoma. 2013 Apr;54 (4) :683-7.|[2]Hernandez-Ilizaliturri FJ1, et al. Immunomodulatory drug CC-5013 or CC-4047 and rituximab enhance antitumor activity in a severe combined immunodeficient mouse lymphoma model. Clin Cancer Res. 2005 Aug 15;11 (16) :5984-92.|[3]Schafer PH, et al. Enhancement of cytokine production and AP-1 transcriptional activity in T cells by thalidomide-related immunomodulatory drugs. J Pharmacol Exp Ther. 2003 Jun;305 (3) :1222-32.|[4]Li Z, et al. Pomalidomide shows significant therapeutic activity against CNS lymphoma with a major impact on the tumor microenvironment in murine models. PLoS One. 2013 Aug 5;8 (8) :e71754.|[5]Lu J, et al. Hijacking the E3 Ubiquitin Ligase Cereblon to Efficiently Target BRD4. Chem Biol. 2015 Jun 18;22 (6) :755-63.|[6]Liu D, et al. Tumour necrosis factor-α inhibits hepatic lipid deposition through GSK-3β/β-catenin signaling in juvenile turbot (Scophthalmus maximus L.) . Gen Comp Endocrinol. 2016 Mar 1;228:1-8.